Previous 10 | Next 10 |
Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor in multiple RAS/MAPK pathway-driven tumors Initial SEACRAFT-1 Phase 1b combination data in RAS Q61X solid tumors expected between Q2-Q4 2024 Initiation of pivotal SEACRAFT-2 in NRASm melanoma expected ...
SAN DIEGO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 6 t...
SAN DIEGO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 42 ...
2023-12-20 13:34:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Although extremely risky, penny stocks can provide tactical value to a portfolio. The risk of losing it all is very real. Also, one should be willing to cut one’s losses if necessary...
First-in-class and best-in-class potential in NRAS-mutated melanoma and other RAS/MAPK pathway-altered solid tumors Naporafenib has been dosed in more than 500 patients to date, establishing its safety, tolerability, and preliminary proof-of-concept in multiple indications Pivotal...
2023-12-08 10:07:46 ET Penny stocks , defined as stocks trading under $5 per share, are known for their volatility. Even small pieces of news or unconfirmed rumors can send some penny stocks swinging wildly up or down in price. This extreme sensitivity makes them risky but also ...
2023-12-07 15:36:49 ET Penny stocks – the cheap stocks trading under $5 per share, offer investors massive upside potential alongside higher risk. Since even incremental price moves translate into huge percentage gains in the stock market, timing entries right can set you up for ...
2023-12-07 11:18:14 ET More on Erasca Seeking Alpha’s Quant Rating on Erasca Historical earnings data for Erasca Financial information for Erasca For further details see: Erasca CEO Lim buys stock worth $1.7M - filing
2023-12-07 10:22:26 ET More on Erasca Seeking Alpha’s Quant Rating on Erasca Historical earnings data for Erasca Financial information for Erasca For further details see: Erasca director Alexander Casdin discloses purchase of 30K shares
2023-12-07 08:27:08 ET MicroAlgo ( MLGO ) +74% plans to establish a practice base to train graduate students for the university. Altisource Asset Management ( AAMC ) +23% Asset case against six defendants in suit v. BlackRock, Pimco can proceed. ...
News, Short Squeeze, Breakout and More Instantly...
Erasca Inc. Company Name:
ERAS Stock Symbol:
NASDAQ Market:
Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor for multiple RAS/MAPK pathway-driven tumors and has been dosed in over 500 patients to date Favorable mOS and mPFS demonstrated in pooled analysis of Phase 1b and Phase 2 trials in NRASm melanoma Randomi...
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that Jonathan E. Lim, M.D., cha...
SAN DIEGO, May 21, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the closing of an oversubscribed und...